GlassScriptPhysician profile
Vindyha Katpally
NPI 1366722480
$984.83
in general payments reported to CMS, 2019-2025
15 companies · $46.95 in 2025
The $46.95 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.82 · 2020: $50.76 · 2021: $71.46 · 2022: $134 · 2023: $216 · 2024: $449 · 2025: $46.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $204.22 | 2020-2024 | Xarelto |
| Gilead Sciences, INC. | $141.72 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $124.50 | 2022-2024 | Eliquis |
| Pfizer INC. | $123.82 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $120.77 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $83.81 | 2024 | |
| Smith+Nephew, INC. | $37.68 | 2024 | Collagenase Santyl |
| Penumbra, INC. | $25.00 | 2025 | Indigo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.79 | 2024 | Lifevest |
| Alexion Pharmaceuticals, INC. | $20.44 | 2023 | Ultomiris |
| Lexicon Pharmaceuticals, INC. | $18.61 | 2023 | Inpefa |
| Lantheus Medical Imaging, INC. | $16.82 | 2019 | |
| Abbvie INC. | $16.15 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.05 | 2022 | |
| Dexcom, INC. | $13.45 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vindyha Katpally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.